The European healthcare technology (HealthTech) mergers and acquisitions (M&A) market is navigating a period of cautious yet discernible rebound in 2025. This resurgence is primarily propelled by improving macroeconomic conditions, substantial private equity dry powder and a pervasive strategic imperative for digital transformation across the healthcare ecosystem.

Private equity firms have traditionally focused on investing in large, high-growth healthcare technology companies. However, there is a growing opportunity for private equity firms to tap into the midtier of the healthtech landscape. These midtier companies have demonstrated a proof of concept, have won flagship customers, and are consistently profitable. However, they are unlikely to reach billion-dollar valuations. This makes them attractive targets for private equity fi